Clinical Trial

A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Researchers are looking for new ways to treat people with B-cell cancers. In this trial, researchers will look at chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These are blood cancers that affect B-cells in the blood, bone marrow, or lymph nodes. The goals of this trial are to learn about: * The safety of MK-1045 and if participants tolerate it. Tolerate means participants will receive trial treatment unless they need to stop treatment due to health problems. * The number of participants who respond. Respond means the number of cancer cells goes down or signs of cancer go away.
Trial Details
NCT Number NCT07709000
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic Malignancies
Enrollment 60 participants
Start Date 2026-08-21
Primary Completion 2033-11-16 (estimated)
Study Completion 2033-11-16 (estimated)
Updated on ClinicalTrials.gov 2026-07-16